MARKET

AMRN

AMRN

Amarin
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.85
-0.18
-2.96%
Opening 15:36 03/03 EST
OPEN
6.06
PREV CLOSE
6.03
HIGH
6.16
LOW
5.75
VOLUME
5.46M
TURNOVER
--
52 WEEK HIGH
16.47
52 WEEK LOW
3.360
MARKET CAP
2.30B
P/E (TTM)
-115.4162
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid
Zacks.com · 5d ago
Amarin Q4 results led by strong Vascepa sales
Amarin Corp. plc (AMRN) reported Q4 2020 results today that beat analyst expectations on both EPS and revenue.Revenue in the quarter was $167.3M, a 17% increase from the prior-year period,
Seekingalpha · 6d ago
The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 24)
Benzinga · 6d ago
8-K: AMARIN CORP PLC\UK
(EDGAR Online via COMTEX) -- AMARIN CORP PLC\UK 00-0000000 false 0000897448 0000897448 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 6d ago
BRIEF-Amarin Reports Fourth Quarter And Full Year Results, Provides Update
reuters.com · 6d ago
Amarin Corp Q4 EPS $0.04 Beats $(0.01) Estimate, Sales $167.30M Beat $164.94M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent increase over earnings of $0.02 per share from the same
Benzinga · 6d ago
Amarin EPS beats by $0.04, beats on revenue
Amarin (AMRN): Q4 Non-GAAP EPS of $0.04 beats by $0.04; GAAP EPS of $0.01 beats by $0.02.Revenue of $167.25M (+16.7% Y/Y) beats by $3.04M.The Co. Received Positive CHMP Opinion for VAZKEPA® in Europe and
Seekingalpha · 6d ago
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
GlobeNewswire · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AMRN. Analyze the recent business situations of Amarin through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AMRN stock price target is 10.64 with a high estimate of 19.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 493
Institutional Holdings: 202.77M
% Owned: 51.51%
Shares Outstanding: 393.64M
TypeInstitutionsShares
Increased
42
28.82M
New
91
-13.59M
Decreased
84
13.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.78%
Pharmaceuticals & Medical Research
-1.77%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
John Thero
Chief Financial Officer/Senior Vice President/Assistant Secretary
Michael Kalb
Executive Vice President/General Counsel/Secretary
Joseph Kennedy
Senior Vice President/Chief Scientific Officer
Stephen Ketchum
Senior Vice President
Aaron Berg
Non-Executive Independent Director
Patrick O'Sullivan
Non-Executive Independent Director
Kristine Peterson
Non-Executive Independent Director
David Stack
Other
Craig Granowitz
Non-Executive Independent Director
Jan van Heek
Non-Executive Independent Director
Joseph Zakrzewski
Non-Executive Independent Director
G. van Heek
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About AMRN
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Webull offers kinds of Amarin Corporation plc (ADR) stock information, including NASDAQ:AMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMRN stock methods without spending real money on the virtual paper trading platform.